Pre-order Enquiry
Request Free Sample
Global Secondary Hyperparathyroidism Treatment Market Size, Status and Forecast 2019-2025
SKU ID : QYR-14227725 | Publishing Date : 17-May-2019 | No. of pages : 96
Secondary hyperparathyroidism refers to the excessive secretion of parathyroid hormone by the parathyroid glands in response to hypocalcemia and associated hyperplasia of the glands.
In the treatment of secondary hyperparathyroidism due to chronic kidney disease on dialysis calcimimetics do not appear to affect the risk of early death. It does decrease the need for a parathyroidectomy but caused more issues with low blood calcium levels and vomiting.
In 2018, the global Secondary Hyperparathyroidism Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Secondary Hyperparathyroidism Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Secondary Hyperparathyroidism Treatment development in United States, Europe and China.
The key players covered in this study
Amgen
OPKO Health
AbbVie
Astellas Pharma
Roche
KAI Pharmaceuticals
Kyowa Hakko Kirin
Leo Pharma
Shire
Sanofi
Deltanoid Pharmaceuticals
Market segment by Type, the product can be split into
Surgery
Drugs
Vitamin D
Calcimimetics
Phosphate Binders
Market segment by Application, split into
Hospital Pharmacies
Retail Pharmacies
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Secondary Hyperparathyroidism Treatment status, future forecast, growth opportunity, key market and key players.
To present the Secondary Hyperparathyroidism Treatment development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Secondary Hyperparathyroidism Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
In the treatment of secondary hyperparathyroidism due to chronic kidney disease on dialysis calcimimetics do not appear to affect the risk of early death. It does decrease the need for a parathyroidectomy but caused more issues with low blood calcium levels and vomiting.
In 2018, the global Secondary Hyperparathyroidism Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Secondary Hyperparathyroidism Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Secondary Hyperparathyroidism Treatment development in United States, Europe and China.
The key players covered in this study
Amgen
OPKO Health
AbbVie
Astellas Pharma
Roche
KAI Pharmaceuticals
Kyowa Hakko Kirin
Leo Pharma
Shire
Sanofi
Deltanoid Pharmaceuticals
Market segment by Type, the product can be split into
Surgery
Drugs
Vitamin D
Calcimimetics
Phosphate Binders
Market segment by Application, split into
Hospital Pharmacies
Retail Pharmacies
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Secondary Hyperparathyroidism Treatment status, future forecast, growth opportunity, key market and key players.
To present the Secondary Hyperparathyroidism Treatment development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Secondary Hyperparathyroidism Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Request Sample
Request Discount
